​

Charles River Laboratories (CRL) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

CRL Stock Forecast

Charles River Laboratories (CRL) stock forecast, based on 37 Wall Street analysts, predicts a 12-month average price target of $308.36, with a high of $357.00 and a low of $219.00. This represents a -8.64% decline from the last price of $337.52.

$150 $200 $250 $300 $350 $400 High: $357 Avg: $308.36 Low: $219 Last Closed Price: $337.52

CRL Stock Rating

Charles River Laboratories stock's rating consensus is Buy, based on 37 Wall Street analysts. The breakdown includes 1 Strong Buy (2.70%), 27 Buy (72.97%), 9 Hold (24.32%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 37 9 27 1 Strong Sell Sell Hold Buy Strong Buy

CRL Price Target Upside V Benchmarks

TypeNameUpside
StockCharles River Laboratories-8.64%
SectorHealthcare Stocks 15.45%
IndustryDiagnostics & Research Stocks5.40%

Price Target Trends

1M3M12M
# Anlaysts11340
Avg Price Target$340.00$321.69$258.80
Last Closing Price$337.52$337.52$337.52
Upside/Downside0.73%-4.69%-23.32%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Nov, 2631121-17
Oct, 2641121-18
Sep, 264921-16
Aug, 263931-16
Jul, 2641021-17
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 12, 2026Morgan Stanley$340.00$301.1512.90%0.73%
Sep 30, 2026Kevin CaliendoUBS$357.00$295.9620.62%5.77%
Sep 28, 2026David WindleyJefferies$340.00$292.8416.10%0.73%
Sep 25, 2026Justin BowersDeutsche Bank$320.00$291.169.91%-5.19%
Sep 25, 2026RBC Capital$322.00$291.1110.61%-4.60%
Sep 25, 2026Evercore ISI$330.00$294.4412.08%-2.23%
Sep 25, 2026Robert W. Baird$334.00$294.4413.44%-1.04%
Sep 25, 2026Ann HynesMizuho Securities$295.00$294.440.19%-12.60%
Sep 25, 2026Barclays$330.00$294.4412.08%-2.23%
Sep 17, 2026Argus Research$330.00$279.4018.11%-2.23%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 12, 2026Morgan StanleyOverweightOverweighthold
Sep 28, 2026JefferiesBuyBuyhold
Sep 25, 2026Deutsche BankBuyBuyhold
Sep 25, 2026RBC CapitalOutperformOutperformhold
Sep 25, 2026Cowen & Co.BuyBuyhold
Sep 25, 2026BarclaysOverweightOverweighthold
Sep 11, 2026Evercore ISIOutperformOutperformhold
Aug 10, 2026Cowen & Co.BuyBuyhold
Aug 07, 2026Morgan StanleyOverweightOverweighthold
Aug 06, 2026RBC CapitalOutperformOutperformhold

Financial Forecast

EPS Forecast

$-5 $0 $5 $10 $15 $20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$7.77$9.57$9.27$0.20$-2.91---
Avg Forecast$10.26$10.89$10.59$10.19$9.88$11.00$12.43$14.23
High Forecast$10.51$11.15$10.68$10.30$12.56$12.63$15.07$15.26
Low Forecast$9.96$10.70$10.45$10.12$9.10$9.71$10.39$13.52
Surprise %-24.27%-12.12%-12.46%-98.04%-129.45%---

Revenue Forecast

$3B $3B $4B $4B $5B $5B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$3.54B$3.98B$4.13B$4.05B$4.02B---
Avg Forecast$3.52B$3.91B$4.11B$4.03B$3.93B$4.16B$4.37B$4.63B
High Forecast$3.59B$3.98B$4.12B$4.05B$4.07B$4.18B$4.42B$4.89B
Low Forecast$3.44B$3.86B$4.10B$4.02B$3.77B$4.15B$4.31B$4.46B
Surprise %0.50%1.64%0.55%0.47%2.23%---

Net Income Forecast

$-150M $40M $230M $420M $610M $800M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$390.98M$486.23M$474.62M$10.30M$-144.34M---
Avg Forecast$364.08M$454.69M$474.62M$525.43M$557.17M$574.85M$654.91M$732.15M
High Forecast$436.89M$545.62M$569.55M$530.07M$646.04M$650.02M$775.34M$785.01M
Low Forecast$291.26M$363.75M$379.70M$520.79M$468.30M$499.69M$534.47M$695.76M
Surprise %7.39%6.94%--98.04%-125.91%---

CRL Forecast FAQ

Is Charles River Laboratories stock a buy?

Charles River Laboratories stock has a consensus rating of Buy, based on 37 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 27 Buy, 9 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Charles River Laboratories is a favorable investment for most analysts.

What is Charles River Laboratories's price target?

Charles River Laboratories's price target, set by 37 Wall Street analysts, averages $308.36 over the next 12 months. The price target range spans from $219 at the low end to $357 at the high end, suggesting a potential -8.64% change from the previous closing price of $337.52.

How does Charles River Laboratories stock forecast compare to its benchmarks?

Charles River Laboratories's stock forecast shows a -8.64% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the diagnostics & research stocks industry (5.40%).

What is the breakdown of analyst ratings for Charles River Laboratories over the past three months?

  • November 2026: 17.65% Strong Buy, 64.71% Buy, 11.76% Hold, 5.88% Sell, 0% Strong Sell.
  • October 2026: 22.22% Strong Buy, 61.11% Buy, 11.11% Hold, 5.56% Sell, 0% Strong Sell.
  • September 2026: 25.00% Strong Buy, 56.25% Buy, 12.50% Hold, 6.25% Sell, 0% Strong Sell.

What is Charles River Laboratories’s EPS forecast?

Charles River Laboratories's average annual EPS forecast for its fiscal year ending in December 2026 is $11, marking a -478.01% decrease from the reported $-2.91 in 2025. Estimates for the following years are $12.43 in 2027, and $14.23 in 2028.

What is Charles River Laboratories’s revenue forecast?

Charles River Laboratories's average annual revenue forecast for its fiscal year ending in December 2026 is $4.16B, reflecting a 3.68% increase from the reported $4.02B in 2025. The forecast for 2027 is $4.37B, and $4.63B for 2028.

What is Charles River Laboratories’s net income forecast?

Charles River Laboratories's net income forecast for the fiscal year ending in December 2026 stands at $574.85M, representing a -498.27% decrease from the reported $-144M in 2025. Projections indicate $654.91M in 2027, and $732.15M in 2028.